Pulmonx to Present at the Citi 2025 Unplugged Medtech and Life Sciences Access Day
Pulmonx (Nasdaq: LUNG), a pioneer in minimally invasive treatments for severe lung disease, has announced its participation in an upcoming investor event. The company will engage in a fireside chat at the Citi 2025 Unplugged Medtech and Life Sciences Access Day in New York on February 27, 2025, at 8:00 AM PT / 11:00 AM ET.
Interested parties can access both live and archived versions of the presentation through the 'Investors' section of the Pulmonx website at investors.pulmonx.com.
Pulmonx (Nasdaq: LUNG), pioniere nei trattamenti minimamente invasivi per gravi malattie polmonari, ha annunciato la sua partecipazione a un prossimo evento per investitori. L'azienda parteciperà a un incontro informale al Citi 2025 Unplugged Medtech and Life Sciences Access Day a New York il 27 febbraio 2025, alle 8:00 AM PT / 11:00 AM ET.
Le parti interessate possono accedere sia alla versione in diretta che a quella archiviata della presentazione attraverso la sezione 'Investitori' del sito web di Pulmonx all'indirizzo investors.pulmonx.com.
Pulmonx (Nasdaq: LUNG), pionero en tratamientos mínimamente invasivos para enfermedades pulmonares severas, ha anunciado su participación en un próximo evento para inversores. La empresa participará en una charla informal en el Citi 2025 Unplugged Medtech and Life Sciences Access Day en Nueva York el 27 de febrero de 2025, a las 8:00 AM PT / 11:00 AM ET.
Las partes interesadas pueden acceder tanto a la versión en vivo como a la archivada de la presentación a través de la sección 'Inversores' del sitio web de Pulmonx en investors.pulmonx.com.
Pulmonx (Nasdaq: LUNG)는 중증 폐 질환을 위한 최소 침습 치료의 선구자로서, 다가오는 투자자 행사에 참여한다고 발표했습니다. 이 회사는 Citi 2025 Unplugged Medtech and Life Sciences Access Day에서 뉴욕에서 2025년 2월 27일, 오전 8:00 PT / 오전 11:00 ET에 화로 토크에 참여할 예정입니다.
관심 있는 분들은 Pulmonx 웹사이트의 '투자자' 섹션을 통해 발표의 실시간 및 아카이브 버전에 접근할 수 있습니다. 주소는 investors.pulmonx.com입니다.
Pulmonx (Nasdaq: LUNG), un pionnier des traitements peu invasifs pour les maladies pulmonaires sévères, a annoncé sa participation à un prochain événement pour investisseurs. L'entreprise participera à une discussion informelle lors du Citi 2025 Unplugged Medtech and Life Sciences Access Day à New York le 27 février 2025, à 8h00 PT / 11h00 ET.
Les parties intéressées peuvent accéder à la version en direct et à l'archive de la présentation via la section 'Investisseurs' du site web de Pulmonx à l'adresse investors.pulmonx.com.
Pulmonx (Nasdaq: LUNG), ein Pionier in der minimal-invasiven Behandlung schwerer Lungenerkrankungen, hat seine Teilnahme an einer bevorstehenden Investorenveranstaltung angekündigt. Das Unternehmen wird an einem Fireside-Chat beim Citi 2025 Unplugged Medtech and Life Sciences Access Day in New York am 27. Februar 2025, um 8:00 AM PT / 11:00 AM ET teilnehmen.
Interessierte können sowohl auf die Live- als auch auf die aufgezeichnete Version der Präsentation über den Bereich 'Investoren' auf der Website von Pulmonx unter investors.pulmonx.com zugreifen.
- None.
- None.
REDWOOD CITY, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the Citi 2025 Unplugged Medtech and Life Sciences Access Day in New York on Thursday, February 27, 2025, at 8:00 AM PT / 11:00 AM ET.
A live and archived webcast of the presentation will be available on “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.
About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System, LungTraX™ Platform, and StratX® Lung Analysis Report are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit www.Pulmonx.com.
Contact
Brian Johnston
Gilmartin Group
investors@pulmonx.com
FAQ
When is Pulmonx (LUNG) presenting at the Citi 2025 Unplugged Medtech Conference?
How can investors watch Pulmonx's (LUNG) presentation at the Citi 2025 conference?
What type of presentation will Pulmonx (LUNG) give at the Citi 2025 conference?
Where is the Citi 2025 Unplugged Medtech conference featuring Pulmonx (LUNG) being held?
